This sub-analysis of a prospective observational study evaluated clinical outcomes in patients with breast cancer who received myelosuppressive chemotherapy and G-CSF support as pegfilgrastim OBI or other options for prophylaxis of FN. The gene discussed is CSF3; the disease is breast carcinoma.